VolitionRx (NYSE:VNRX) Issues Earnings Results

VolitionRx (NYSE:VNRX) posted its quarterly earnings results on Monday. The company reported ($0.11) EPS for the quarter, Zacks reports. The business had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $0.50 million. VolitionRx had a negative net margin of 4,557.29% and a negative return on equity of 7,185.73%.

VolitionRx Price Performance

VolitionRx stock opened at $0.75 on Wednesday. VolitionRx has a 1 year low of $0.55 and a 1 year high of $2.10. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.69 and a current ratio of 0.69. The firm has a 50 day moving average price of $1.00 and a 200 day moving average price of $0.87. The company has a market cap of $59.00 million, a price-to-earnings ratio of -1.47 and a beta of 1.38.

Hedge Funds Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Vanguard Group Inc. increased its position in VolitionRx Limited (NYSE:VNRX) by 4.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 542,444 shares of the company’s stock after buying an additional 22,046 shares during the quarter. Vanguard Group Inc. owned about 0.69% of VolitionRx worth $374,000 as of its most recent filing with the Securities and Exchange Commission. 8.09% of the stock is currently owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.